Solaris Pharma Launches Generic Briviact®️ to Improve Access to Epilepsy Treatment
Solaris Pharma has launched brivaracetam tablets — the generic equivalent of UCB's Briviact® — marking a notable pivot for a company long anchored in...
XOCOVA®️ Becomes First-Ever Oral Pill Approved to Prevent COVID-19 After Exposure
A historic milestone in pandemic preparedness arrived this week as the U.S. Food and Drug Administration granted approval to XOCOVA® (ensitrelvir) — the world’s...
AstraZeneca’s Ultomiris®️ Cuts Proteinuria by 43.4% in Phase – 3 Trial
Alexion, AstraZeneca Rare Disease, announced positive results from a prespecified interim analysis of the global Phase III I CAN trial. The data demonstrate...
Lupin Gets U.S. FDA Approval for Ranluspec™ to Treat Retinal Disorders
Lupin Limited has secured U.S. FDA approval for Ranluspec™ (ranibizumab-hkdz), an interchangeable biosimilar to Genentech’s Lucentis® — a milestone that reshapes patient access to sight-saving biologics across...
India’s Lupin and Natco Pharma Secure U.S. FDA Approval for Eribulin Mesylate Injection
On 03rd June, 2026 Lupin Limited (Lupin) announced that, Lupin and its alliance partner Natco Pharma Limited (Natco) got the approval from the United States Food and Drug Administration (U.S. FDA)...
Lilly’s Obesity Portfolio Wins Full U.S. Insurance Coverage, Reshaping the GLP-1 Landscape
In a pivotal shift for the obesity treatment market, Eli Lilly and Company (NYSE: LLY) has secured formulary coverage across all three of America's...